Opioid use disorder among pregnant women in the 2000–2014 North Carolina state inpatient database

Alemu, Brook T.; Beydoun, Hind A.; Olayinka, Olaniyi; Young, Beth

doi:10.1080/10550887.2020.1751023

Cited by 8 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is both noteworthy and significant when compared with the much smaller 4.6% of pregnant women in the United States who delayed prenatal care presentation until the third trimester and the 1.6% of pregnant women in the United States who received no prenatal care in 2016 20 . The increased rates of adverse maternal and fetal health outcome experience by this cohort are well known and have been illustrated by several other studies that describe the complications that can occur when pregnancy is impacted by opioid misuse 21–23 . When not recognized and treated, opioid misuse and OUD during pregnancy pose a substantial threat to both mother and fetus.…”

Section: Discussionmentioning

confidence: 86%

“…20 The increased rates of adverse maternal and fetal health outcome experience by this cohort are well known and have been illustrated by several other studies that describe the complications that can occur when pregnancy is impacted by opioid misuse. [21][22][23] When not recognized and treated, opioid misuse and OUD during pregnancy pose a substantial threat to both mother and fetus. This study also further details the disproportionate socioeconomic challenges this specific population often experiences.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pregnancy, Opioid Use Disorder and COVID-19: An Evaluation of Acute Care Presentations During a Pandemic

et al. 2022

View full text Add to dashboard Cite

IntroductionThe opioid epidemic has been exacerbated by the COVID-19 pandemic, resulting in increased acute care opioid-related and overdose visits. We sought to assess how the pandemic may have impacted an obstetric cohort impacted by opioid misuse in the acute care context.MethodsA retrospective review of acute care presentations of patients with concomitant pregnancy (Z33.1) and opioid-related diagnostic codes (T10 codes and/or F11) was conducted over a 24-month period (pre-COVID = March 2019 through February 2020, post-COVID = March 2020 through February 2021). Descriptive statistics and χ2 analysis of pre- versus post-COVID presentations were performed.ResultsA total of 193 individuals, 104 (53.9%) pre- and 89 (46.1%) post-COVID, accounting for 292 total encounters, 160 (54.8%) pre- and 132 (45.2%) post-COVID, were seen for acute care visits (P = 0.84). Age (P = 0.15), race (P = 0.59), and insurance status (P = 0.17) were similar pre- versus post-COVID. The majority of presentations, pre- (40.4%) and post-COVID (44.9%), were for opioid withdrawal (P = 0.74). Although post-COVID individuals were more likely to lack prenatal care (48.3% versus 39.4% pre-COVID), this trend was not significant (P = 0.19). Similar proportions of individuals were affected by pregnancy complications (51.9% pre-, 44.9% post-COVID; P = 0.30). Similar proportions of individuals were affected by adverse pregnancy outcomes (44.2% pre-, 48.3% post-COVID; P = 0.64).ConclusionThe COVID-19 pandemic did not have a statistically significant effect on opioid-related acute care presentations or outcomes for obstetric patients. In this acute care cohort, however, opioid misuse had significant general impact on pregnancy complications and outcomes, suggesting unmet needs in this population.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Pregnancy, Opioid Use Disorder and COVID-19: An Evaluation of Acute Care Presentations During a Pandemic

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Previous research has shown that compared with unexposed infants, infants with POE and NAS have an increased risk of low birth weight (Lisonkova et al 2019;Nørgaard et al 2015), preterm birth (birth before 37 weeks) (Alemu et al 2020;Brogly et al 2021;Corsi et al 2020;Maeda et al 2014) and stillbirth (Alemu et al 2020;Maeda et al 2014); and have poor fetal growth (Alemu et al 2020;Maeda et al 2014). The teratogenic effects of POE are still not well understood.…”

Section: Perinatal and Infant Health Outcomesmentioning

confidence: 99%

Reviewing the Evidence on Prenatal Opioid Exposure to Inform Child Development Policy and Practice

Camden¹,

Harris²,

Otter-Moore³

et al. 2021

hcq

View full text Add to dashboard Cite

Prenatal opioid use is increasingly common and can have adverse impacts on maternal and child health. In Ontario, there are no clear guidelines or universal programs to support the healthy development of children with prenatal opioid exposure. We present the epidemiology of prenatal opioid exposure in Ontario, summarize research examining child health outcomes with a focus on child development, review emerging guidelines for child health and developmental surveillance and highlight promising programs. We emphasize the need to strengthen current Canadian recommendations for routine enhanced developmental and vision screening and ensure funding for evidence-based integrated maternal/child services.

show abstract

“…It has been demonstrated that the U.S. has experienced a rapid increase in NAS as a result of in-utero opioid exposure due to a combination of prescription and recreational opioid use [4,[28][29][30]. Ailes et al in a CDC report from 2008-2012 showed widespread prescription use in the U.S. among women enrolled in Medicaid compared to those with private insurance [3].…”

Section: Plos Onementioning

confidence: 99%

Disparity in neonatal abstinence syndrome by race/ethnicity, socioeconomic status, and geography, in neonates ≥ 35 weeks gestational age

et al. 2023

View full text Add to dashboard Cite

Neonatal abstinence syndrome (NAS) is associated with a range of adverse health outcomes, exorbitant health care costs, and race/ethnicity disparity. We examined key sociodemographic factors that may influence the national race/ethnicity disparity in the prevalence of NAS among Whites, Blacks and Hispanics. 2016 and 2019 cycles of cross-sectional data from HCUP-KID national all-payer pediatric inpatient-care database were used to estimate NAS prevalence (ICD-10CM code P96.1) in newborns ≥ 35 weeks gestational-age, excluding iatrogenic-cases (ICD-10CM code P96.2). Multivariable generalized-linear-models with predictive-margins were used to produce race/ethnicity-specific stratified-estimates for select sociodemographic factors, reported as risk-differences (RD) with 95% confidence-intervals (CI). Final models were adjusted for sex, payer-type, ecologic income-level, and hospital size, type, and region. The overall survey weighted-sample prevalence of NAS was 0.98% (i.e., 6282/638100) and did not differ over cycles. Blacks and Hispanics were significantly more likely than Whites to be in the lowest ecologic income quartile and on Medicaid. In fully-specified models, NAS prevalence among Whites was 1.45% (95% CI: 1.33, 1.57) higher than Blacks and 1.52% (95% CI: 1.39, 1.64) higher than Hispanics; and NAS among Blacks was 0.14% higher than Hispanics (95% CI: 0.03, 0.24). NAS prevalence was highest among Whites on Medicaid (RD: 3.79%; 95% CI: 3.55, 4.03) compared to Whites on private-insurance (RD: 0.33%; 95% CI: 0.27, 0.38), and Blacks (RD: 0.73%; 95% CI: 0.63, 0.83; RD: 0.15%; 95% CI: 0.08, 0.21), or Hispanics, with either payer-type (RD: 0.59%; 95% CI: 0.5, 0.67; RD: 0.09%; 95% CI: 0.03, 0.15) respectively. NAS prevalence was higher among Whites in the lowest income-quartile (RD: 2.22%; 95% CI: 1.99, 2.44) compared with Blacks (RD: 0.51%; 95% CI: 0.41, 0.61) and Hispanics (RD: 0.44%; 95% CI: 0.33, 0.54) in the same quartile, and all subgroups in other quartiles. NAS prevalence was higher among Whites in the Northeast (RD: 2.19%; 95% CI: 1.89, 2.5) compared to Blacks (RD: 0.54%; 95% CI: 0.33, 0.74) and Hispanics (RD: 0.31%; 95% CI: 0.17, 0.45). Although Blacks and Hispanics were more likely to be in the lowest income quartile and have Medicaid insurance, Whites on Medicaid, in the lowest income quartile, and in the Northeast, were found to have the highest NAS prevalence.

show abstract

Opioid use disorder among pregnant women in the 2000–2014 North Carolina state inpatient database

Cited by 8 publications

References 27 publications

Pregnancy, Opioid Use Disorder and COVID-19: An Evaluation of Acute Care Presentations During a Pandemic

Pregnancy, Opioid Use Disorder and COVID-19: An Evaluation of Acute Care Presentations During a Pandemic

Reviewing the Evidence on Prenatal Opioid Exposure to Inform Child Development Policy and Practice

Disparity in neonatal abstinence syndrome by race/ethnicity, socioeconomic status, and geography, in neonates ≥ 35 weeks gestational age

Contact Info

Product

Resources

About